Literature DB >> 10329095

Idiopathic atrial fibrillation as a risk factor for mortality. The Paris Prospective Study I.

X Jouven1, M Desnos, C Guerot, P Ducimetiere.   

Abstract

AIMS: Idiopathic atrial fibrillation describes atrial fibrillation of unknown origin occurring without heart disease. Mortality is considered unaffected by idiopathic atrial fibrillation. We used the long follow-up period (23 years on average) of the Paris Prospective Study I to assess the mortality of idiopathic atrial fibrillation subjects in middle-aged men.
METHODS: 7746 working Frenchmen, aged 43-52 in 1967-72, underwent a physical examination plus ECG, answered questionnaires, and provided blood samples. Strict exclusion criteria were used to select idiopathic atrial fibrillation only, and men with known cardiac disease were further excluded from analysis. At 1 January 1994, vital status was unknown for 4.6% of the subjects. The analysis was conducted on the 6722 remaining subjects.
RESULTS: Twenty-five subjects had idiopathic atrial fibrillation at inclusion. The relative risk (and 95% confidence interval) associated with idiopathic atrial fibrillation was 4.22 [2.10-8.47] for cardiovascular mortality (P=0.0001) and 1. 97 [1.14-3.40] for total mortality (P=0.01). When age, systolic blood pressure, cholesterol, body mass index and tobacco consumption were entered into a Cox model, idiopathic atrial fibrillation remained an independent risk factor for cardiovascular (P=0.0008) and total death (P=0.04).
CONCLUSION: With a long follow-up period, idiopathic atrial fibrillation was associated with higher mortality in middle aged Frenchmen. Copyright 1999 The European Society of Cardiology.

Entities:  

Mesh:

Year:  1999        PMID: 10329095     DOI: 10.1053/euhj.1998.1397

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  12 in total

1.  Atrial fibrillation: now one of the most common causes for hospitalization.

Authors:  Joseph S Alpert
Journal:  Curr Cardiol Rep       Date:  2005-05       Impact factor: 2.931

2.  [Outcome parameters for AF trials--executive summary of an AFNET-EHRA consensus conference].

Authors:  P Kirchhof; A Goette; G Hindricks; S Hohnloser; K-H Kuck; T Meinertz; U Ravens; G Steinbeck; G Breithardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-12

3.  Rate control versus electrical cardioversion for atrial fibrillation: A randomised comparison of two treatment strategies concerning morbidity, mortality, quality of life and cost-benefit - the RACE study design.

Authors:  I C van Gelder; V E Hagens; J H Kingma; H A Bosker; O Kamp; T Kingma; N J G M Veeger; J Bouma; E M TenVergert; J G P Tijssen; H J G M Crijns
Journal:  Neth Heart J       Date:  2002-03       Impact factor: 2.380

4.  Prevalences of ECG findings in large population based samples of men and women.

Authors:  D De Bacquer; G De Backer; M Kornitzer
Journal:  Heart       Date:  2000-12       Impact factor: 5.994

Review 5.  Emergency management of atrial fibrillation.

Authors:  A Wakai; J O O'Neill
Journal:  Postgrad Med J       Date:  2003-06       Impact factor: 2.401

Review 6.  Lone atrial fibrillation: does it exist?

Authors:  D George Wyse; Isabelle C Van Gelder; Patrick T Ellinor; Alan S Go; Jonathan M Kalman; Sanjiv M Narayan; Stanley Nattel; Ulrich Schotten; Michiel Rienstra
Journal:  J Am Coll Cardiol       Date:  2014-02-12       Impact factor: 24.094

7.  Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis.

Authors:  Mariëlle Kloosterman; Jonas Oldgren; David Conen; Jorge A Wong; Stuart J Connolly; Alvaro Avezum; Salim Yusuf; Michael D Ezekowitz; Lars Wallentin; Marie Ntep-Gweth; Philip Joseph; Tyler W Barrett; Supachai Tanosmsup; William F McIntyre; Shun Fu Lee; Ratika Parkash; Guy Amit; Alex Grinvalds; Isabelle C Van Gelder; Jeff S Healey
Journal:  Europace       Date:  2020-06-01       Impact factor: 5.214

8.  Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised.

Authors:  Torsten Becker; Thomas Kleemann; Margit Strauss; Klaus Doenges; Steffen Schneider; Jochen Senges; Karlheinz Seidl
Journal:  Clin Res Cardiol       Date:  2007-10-19       Impact factor: 5.460

9.  Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study.

Authors:  Jose Luis Clua-Espuny; Anna Panisello-Tafalla; Carlos Lopez-Pablo; Inigo Lechuga-Duran; Ramon Bosch-Princep; Jorgina Lucas-Noll; Antonia Gonzalez-Henares; Lluisa Queralt-Tomas; Rosa Ripolles-Vicente; Cristina Calduch-Noll; Nuria Gonzalez-Rojas; Miguel Gallofre-Lopez
Journal:  Cardiol Res       Date:  2014-02-27

10.  Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study).

Authors:  Eun-Jeong Kim; Xiaoyan Yin; João D Fontes; Jared W Magnani; Steve A Lubitz; David D McManus; Sudha Seshadri; Ramachandran S Vasan; Patrick T Ellinor; Martin G Larson; Emelia J Benjamin; Michiel Rienstra
Journal:  Am Heart J       Date:  2016-04-30       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.